Amino Acid, Peptide, or Protein
Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval
Zepbound, Eli Lilly, sleep apnea, FDA approval, Novo Nordisk, Wegovy, weight loss, diabetes, pharmaceuticals
BMS’s KRAS Inhibitor Krazati Receives FDA Approval for Colorectal Cancer Treatment
Krazati, Bristol Myers Squibb, FDA approval, colorectal cancer, KRAS inhibitor, adagrasib, cetuximab
Vertex Announces Positive Results for VX-880 in Type 1 Diabetes Treatment
Vertex Pharmaceuticals, VX-880, Type 1 Diabetes, Stem Cell Therapy, Insulin Independence, Severe Hypoglycemic Events
Gilead’s Antibody Finds New Life with $40M Investment in Small Biotech
Gilead, antibody, small biotech, $40M investment, oncology R&D
AbbVie’s Skyrizi Secures Key FDA Approval for Ulcerative Colitis Treatment
Skyrizi, AbbVie, FDA approval, ulcerative colitis, inflammatory bowel disease, IL-23 inhibitor, Crohn’s disease
Amgen’s Blincyto Wins FDA Approval for Expanded Leukemia Use
Blincyto, Amgen, FDA Approval, Leukemia Treatment, Minimal Residual Disease (MRD), Acute Lymphoblastic Leukemia (ALL), Bispecific Antibody
PTC Therapeutics Reports Positive Phase II Huntington’s Disease Data, FDA Lifts Partial Clinical Hold
PTC Therapeutics, Huntington’s disease, Phase II data, FDA, partial clinical hold, PTC518, mutant huntingtin protein, clinical trends, safety, tolerability.
FDA Approves Keytruda for Primary Advanced or Recurrent Endometrial Carcinoma and Skyrizi for Ulcerative Colitis
Keytruda, pembrolizumab, endometrial carcinoma, Skyrizi, risankizumab-rzaa, ulcerative colitis, FDA approval
Lilly Expands Legal Efforts Against Compounded Tirzepatide Sellers, Warns of Counterfeit Risks
Eli Lilly, tirzepatide, Mounjaro, Zepbound, compounded drugs, counterfeit products, legal actions, patient safety
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion